Feature | August 29, 2012| Dave Fornell

Bioresorbable Vascular Closure Devices Speed Ambulation

 An extracted bovine artery with an arteriotomy sealed by a MynxGrip closure dev

An extracted bovine artery with an arteriotomy sealed by a MynxGrip closure device, showing the attached PEG plug that had expanded into the tissue tract.

Vascular closure devices that use an active method to immediately seal the femoral access site can enable faster patient ambulation, reduce nursing time and speed discharge. However, one of the biggest issues interventionalists have with active vascular closure devices is the use of a permanent piece of hardware to stitch or clip the arteriotomy closed. Three companies now offer fully bioresorbable, active vascular closure devices, including a recent release earlier this year.  

In February 2012, the U.S. Food and Drug Administration (FDA) cleared AccessClosure’s new MynxGrip Vascular Closure Device (VCD). Built on the Mynx platform, the MynxGrip VCD adds the company’s patented Grip Technology sealant to the distal end of the original Mynx sealant, resulting in a better seal on the vessel and filling the tissue tract.

Hemostasis is achieved through the delivery of a water-soluble, bio-inert, non-thrombogenic polyethylene glycol (PEG) polymer on the shaft of a delivery catheter to the surface of the artery. The new formulation of PEG adheres better to the contours of the vessel wall. The material swells in size to fill the tissue tract. The sealant fully resorbs within 30 days. A 6 mm semi-compliant balloon is inflated against the arterial wall to establish temporary hemostasis during deployment of the sealant and ensures its extra-arterial placement. The result is an active seal that leaves no foreign material behind inside the vessel. 

Cordis Corp. gained FDA clearance for the Exoseal vascular closure device in May 2011. It incorporates an extravascular, bioabsorbable polyglycolic acid (PGA) plug. It is designed to close the femoral artery puncture site with minimal or no inflammation, is fully reabsorbed in 60-90 days. 

St. Jude Medical’s Angio-Seal line also offers a bioabsorbable active closure system. It includes use of an intra-arterial anchor attached to a suture and a collagen seal.

Related Content

Stryker Sustainability Solutions, Angiodynamics Soft Vu Omni Flush Angiographic Catheters, recall
News | Angiographic Catheter| July 25, 2016
Stryker Sustainability Solutions (formerly Ascent Healthcare Solutions) is recalling Angiodynamics Soft Vu Omni Flush...
Million Hearts Cardiovascular Disease Risk Reduction Model, CMS, reduce heart attacks and strokes, participants
News | Patient Engagement| July 22, 2016
July 22, 2016 — The Centers for Medicare & Medicaid Services (CMS) recently announced 516 awardees in 47 states,
heart failure, after first heart attack, cancer risk, JACC study
News | Cardiac Diagnostics| July 21, 2016
People who develop heart failure after their first heart attack have a greater risk of developing cancer when compared...
Absorb, bioresorbable stent, BVS

The Abbott Absorb stent gained FDA clearance in July 2016. It has metallic markers at each end so it can be visualized for proper positioning under angiographic X-ray imaging. 

Feature | Stents Bioresorbable| July 21, 2016 | Alphonse Ambrosia, D.O.
Some have labeled bioresorbable scaffolds (BRS), also known as bioresorbable stents, as the fourth evolution of inter
Sponsored Content | Videos | Inventory Management| July 19, 2016
You have bigger priorities than managing inventory.
Abbott Absorb bioresorbable stent, dissolving BVS, first West Coast implant, Good Samaritan Hospital Los Angeles
News | Stents Bioresorbable| July 19, 2016
Good Samaritan Hospital, Los Angeles, is the first hospital on the West Coast to offer patients with coronary artery...
Medtronic, In.Pact Admiral drug coated balloon, DCB, FDA approval, 150 mm length
Technology | Drug-Eluting Balloons| July 18, 2016
Medtronic plc has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT Admiral drug-coated balloon...
3-D OCT

A 3-D OCT rendering of a stented vessel segment created on St. Jude Medical's Ilumien Optis OCT system. 

Feature | Angiography| July 15, 2016 | Dave Fornell
While angiographic X-ray fluoroscopy systems are the workhorse for transcatheter cardiovascular interventional proced
VentureMed Group, Flex Scoring Catheter, FDA approval, peripheral arterial disease, PAD, endovascular treatment
Technology | Catheters| July 13, 2016
July 13, 2016 — VentureMed Group Ltd., specializing in devices for the endovascular treatment of...
radial access, inserting stents, JACC Cardiovascular Interventions study
News | Radial Access| July 13, 2016
A new study in JACC: Cardiovascular Interventions supports access through the wrist, or radial access, as the default...
Overlay Init